Investigational drug · Phase 2
MEN2312
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hematological Malignancy.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "MEN2312"
First trial start
2026
Oct 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MEN2312", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hematological Malignancy
Largest trials
Live from ClinicalTrials.gov: studies naming "MEN2312" as an intervention, largest first.
- A First-in-Human Study of MEN2312 in Adults With Advanced Breast CancerPivotal-lookingRecruiting
Stemline Therapeutics, Inc.Industry
NCT06638307 · 240 participants (planned) · Start Oct 25, 2024 · Primary completion Oct 24, 2027
Drug: MEN2312; Elacestrant · For: Advanced Breast Cancer
Sites: Springdale, Arkansas; Duarte, California; La Jolla, California · 47 sites in all
- KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme MalignanciesPivotal-lookingNot yet recruiting
Stemline Therapeutics, Inc.Industry
NCT07873827 · 115 participants (planned) · Start Oct 30, 2026 · Primary completion May 12, 2028
Drug: MEN2312 · For: Hematological Malignancy
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.